At long last, Eisai and Arena Pharmaceuticals have been given the go-ahead to launch their anti-obesity drug Belviq in the USA.
The US Food and Drug Administration approved Belviq (lorcaserin) last June chronic weight management in adults with a body mass index of 30 or greater, or adults with a BMI of 27 who have at least one weight-related condition such as hypertension, type 2 diabetes or high cholesterol. However, the agency said at the time that Belviq be classified by the US Drug Enforcement Administration as a scheduled drug, ie its potential for abuse needed to be evaluated.
This has held up a launch but now the DEA has placed Belviq into Schedule IV of the Controlled Substances Act, which means that the treatment has a low potential for abuse. In 30 days time, Eisai will make the drug available and the launch will trigger a…
View original post 375 more words